Home >
News >
GST and Boehringer Ingelheim awarded Best Mid-Cap Corporate Deal by the Belgian M&A awards
NEWS
GST and Boehringer Ingelheim awarded Best Mid-Cap Corporate Deal by the Belgian M&A awards
19/03/2021
Related Lawyer(s)
Congratulations to Global Stem Cell Technology (GST) and Boehringer Ingelheim for being awarded Best Mid-Cap Corporate Deal by the Belgian M&A awards. A Liedekerke team consisting of partner Wim Dedecker and associates Ellen Vermeire and Max Le Blanc assisted Boehringer Ingelheim on this transaction.
Wim Dedecker adds: “It has been a real privilege working on a deal of such strategic importance, which demonstrates the unique quality of our Belgian biotech ecosystem. Congratulations to all involved – this is very well deserved”
Read more about the deal here.
- Trade associations and competition law challenges for in-house counsel
- How to succesfully navigate the EC purchaser approval process
- Avoiding competition pitfalls in creating and operating JVs
- Tax on Securities Accounts is back
- Brexit and Schrems II?
- Impact of the Covid law of 20 December 2020 on the organisation of general meetings in companies and associations
- The EU Recovery Prospectus
- A guide for corporate governance in Belgium 2021
- Liedekerke contributes to the Legal 500 Corporate Governance Country Comparative Guide 2021
- Liedekerke contributed to the 9th edition of the Cartels and Leniency Review
- View all
partenaire
Liedekerke Wolters Waelbroeck Kirkpatrick
boulevard de l'Empereur 3 Keizerslaan - 1000 Brussels - Belgium
T: +32 2 551 15 15 - F: +32 2 551 14 14
VAT - BE 0478 065 191
boulevard de l'Empereur 3 Keizerslaan - 1000 Brussels - Belgium
T: +32 2 551 15 15 - F: +32 2 551 14 14
VAT - BE 0478 065 191
